The FDA granted approval for Moderna's mFlusiva mRNA flu vaccine for adults 50 and older on August 5, marking the first such approval for a seasonal influenza mRNA product. Traditional approval covers ages 50-64 while accelerated approval applies to those 65 and older pending further data. The decision followed a trial of over 40,000 participants and came after an initial FDA refusal that was later reversed.